Drug Trial Radar · NCT03960866
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
May 28, 2019
Primary completion
Sep 11, 2019
Study completion Sep 11, 2019
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT). * To evaluate the ocular and systemic safety of Phentolamine Mesylate compared to its vehicle. * To evaluate additional efficacy of Phentolamine Mesylate to improve visual performance.
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%Drug
Topical Sterile Ophthalmic Solution
Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Other
Topical Sterile Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular PressureTime frame: 15 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
North Valley Eye Medical Group
Mission Hills, California
Clayton Eye Clinical Research
Morrow, Georgia
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Rochester Ophthalmological Group
Rochester, New York
Abrams Eye Center
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.